Evogene (NASDAQ:EVGN) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Evogene (NASDAQ:EVGN) in a report released on Wednesday. The firm issued a sell rating on the biotechnology company’s stock.

Evogene Trading Down 5.0 %

NASDAQ EVGN opened at $0.63 on Wednesday. The business’s fifty day moving average is $0.79 and its 200 day moving average is $0.74. Evogene has a fifty-two week low of $0.45 and a fifty-two week high of $1.44.

Evogene (NASDAQ:EVGN) last posted its quarterly earnings data on Thursday, March 7th. The biotechnology company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.01. The firm had revenue of $0.58 million for the quarter, compared to the consensus estimate of $1.73 million. Evogene had a negative return on equity of 76.93% and a negative net margin of 423.39%. During the same quarter last year, the company earned ($0.07) earnings per share.

Institutional Trading of Evogene

An institutional investor recently raised its position in Evogene stock. Silverarc Capital Management LLC raised its holdings in shares of Evogene Ltd. (NASDAQ:EVGN) by 3,000.0% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,100,000 shares of the biotechnology company’s stock after acquiring an additional 3,000,000 shares during the quarter. Silverarc Capital Management LLC owned approximately 7.52% of Evogene worth $1,818,000 as of its most recent SEC filing. 10.40% of the stock is currently owned by institutional investors.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.